

VIDAS® ANTI-MÜLLERIAN HORMONE On-hand testing for greater patient comfort

F ...



SA

Did you know?



1/6 couples worldwide experience some form of infertility ⁽¹⁾


Polycystic Ovary Syndrome (PCOS) affects **5-10%** of women of reproductive age ⁽²⁾

In 30 years, the success rate of IVF has increased from 10% to above 30% (3)

Anti-Müllerian Hormone (AMH) testing for ovarian function assessment in women

AMH FEATURES

Stable over the menstrual cycle



cycle of young healthy women (4)Day 0 = day of LH surge

Sensitive to conformational change in samples (5)

More accurate than Antral Follicular Count (AFC)

- Inter-operator variation makes AFC subjective
- AMH provides quantitative objective results ⁽⁶⁾
- A key test within the diagnostic work-up

VIDAS® Anti-Müllerian Hormone

On-hand quality testing for confident decisions **Reliability and robustness**

Greater reliability through patented proprietary raw materials → Reliable results when compared with an existing automated method* → Minimal impact of pre-analytical stage on test results:

≤ 8 hours at +18/+25°C in closed primary tube



 \leq 8 hours



VIDAS[®]: an easy-to-use benchtop platform

- Just load & go
- Limited calibration and maintenance
- Compact instrument: easily fits into your fertility center or laboratory

24/7 availability for your patients' comfort

A COMPLETE SOLUTION ON YOUR VIDAS® INSTRUMENT		1 pat
HORMONE ASSAYS AMH ESTRADIOL FSH LH HCG PROLACTIN PROGESTERONE TESTOSTERONE	SEROLOGY PANELS • HEPATITIS • HIV • TORC	• On-c • Res i

- THYROID PANEL

→ Adapt treatment

the reproductive lifespan:

(IVF/ART):

investigations

→ Avoid unnecessary stimulation

CLINICAL APPLICATIONS

As an indicator of the ovarian follicle reserve.

Personalization of infertility management

AMH is useful in different contexts all along

Assessment of ovarian reserve for infertility

Help to select the best stimulation protocol

 \rightarrow Reduce risk of hyperstimulation syndrome

Detection of ovarian dysfunction (PCOS, Premature ovarian failure...):

The use of AMH rather than Follicle Stimulating Hormone (FSH) or Luteinizing Hormone (LH) provides direct, more accurate assessment of ovulation.

Monitoring of ovarian damage(surgery, gonadotoxic therapies)

First-choice marker to detect the decline of the ovarian reserve.





VIDAS® COMMUNITY: partnering over 30 000 users worldwide

tient = 1 test for maximum flexibility

demand testing

sults during the consultation

- \rightarrow Less patient stress
- → Immediate integration of AMH results into the full diagnostic work-up
- → Treatment optimization
- → No unnecessary ovarian stimulation



AVAILABLE ON VIDAS® INSTRUMENTS VIDAS®, MINI VIDAS® AND VIDAS® 3



	VIDAS [®] AMH
Reference number	417011
Tests / kit	30
Time to result	35 min
Sample type	Serum, Plasma (Li Hep)
Sample volume	200 µL
Units	ng/mL - pmol/L
Measuring range	0.02 – 9.00 ng/mL
Calibration & Control frequency	28 days

REFERENCES

1. https://www.eshre.eu/Guidelines-and-legal/ART-fact-sheet

2. https://www.pcosfoundation.org/ 3. https://www.sart.org/History_of_IVF/

4. La Marca et al Human Reproduction 2006

5. Rustamov O et al Human Reproduction 2012

6. Anderson RA et al Fertility and Sterility 2015

12-18/9316061 008/GB/B / Document and/or pictures not legally binding. Modifications by bioMérieux can be made without prior notice / BIOMÉREUX. the BIOMÉRIEUX logo and VIDAS are used, pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries or one of its companies. Any other trademark is the property of its respective owner. / bioMérieux S.A. RCS Iyon 673 620 339 / Printed in France / **thera**? RCS Iyon B 398 160 242.